Skip to main content

Table 3 Details on CMV infection during 36 months

From: Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial

Characteristic

Valganciclovir (n = 60)

Valacyclovir (n = 59)

P Value

CMV Disease

5 (9)

1 (2)

0.115a

CMV Disease by D/R status

   

 D+/R-

3 (49)

0 (0)

0.125

 D+/R+

2 (5)

1 (2)

0.555

 D−/R+

0 (0)

0 (0)

–

CMV DNAemia

21 (36)

24 (42)

0.361a

CMV DNAemia by D/R status

   

 D+/R-

4 (64)

2 (50)

0.986

 D+/R+

14 (32)

21 (45)

0.180

 D−/R+

5 (50)

1 (17)

0.264

Peak viral load (copies/mL)

350 (100–6150)

850 (100–1650)

0.982

Duration of CMV DNAemia (d)

40 (27–78)

31 (15–69)

0.270

  1. Data are number of patients (percentage) or median and interquartile range. CMV, cytomegalovirus; D, donor; R, recipient
  2. aCMV Disease: adjusted hazard ratio, 4.96; 95% confidence interval, 0.57–43.1; P = 0.147; CMV DNAemia: adjusted hazard ratio, 0.78; 95% confidence interval, 0.43–1.42; P = 0.418 by multivariate Cox proportional hazard model after adjustment for calcineurin inhibitor, induction therapy, and advanced chronic histologic damage in donor biopsy